{"id":77735,"date":"2013-05-03T09:53:14","date_gmt":"2013-05-03T13:53:14","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/bg-medicine-to-announce-first-quarter-2013-financial-results-and-host-conference-call-on-thursday-may-9-2013.php"},"modified":"2013-05-03T09:53:14","modified_gmt":"2013-05-03T13:53:14","slug":"bg-medicine-to-announce-first-quarter-2013-financial-results-and-host-conference-call-on-thursday-may-9-2013","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/bg-medicine-to-announce-first-quarter-2013-financial-results-and-host-conference-call-on-thursday-may-9-2013.php","title":{"rendered":"BG Medicine to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 9, 2013"},"content":{"rendered":"<p><p>      WALTHAM, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- BG Medicine,      Inc. (BGMD)      today announced that the company will host a conference call      and webcast on Thursday, May 9 at 8:30 a.m. Eastern Time to      discuss its first quarter 2013 financial results. The call      and webcast will follow the release of first quarter      financial results before the market opens.    <\/p>\n<p>      Conference Call Details    <\/p>\n<p>      To access the live conference call on Thursday, May      9th at 8:30 a.m. Eastern Time via phone, please      dial (877) 845-1016 from the U.S. and Canada, or (708)      290-1155 internationally. Please dial in approximately ten      minutes prior to the start of the call.    <\/p>\n<p>      To access the live and subsequently archived webcast of the      conference call, go to the Investor Relations section of the      company's website       <a href=\"http:\/\/investor.bg-medicine.com\/events.cfm\" rel=\"nofollow\">http:\/\/investor.bg-medicine.com\/events.cfm<\/a>.      Please connect to the website at least 15 minutes prior to      the call to allow for any software download that may be      necessary.    <\/p>\n<p>      About BG Medicine    <\/p>\n<p>      BG Medicine, Inc. (BGMD)      is a diagnostics company focused on the development and      commercialization of novel cardiovascular tests to address      significant unmet medical needs, improve patient outcomes and      reduce healthcare costs. The Company has two products: the      BGM Galectin-3(R) test for use in patients with chronic heart      failure is available in the United States and Europe; and the      CardioSCORE(TM) test for the risk prediction of major      cardiovascular events will be launched in Europe in the first      half of 2013. For additional information about BG Medicine,      heart failure and galectin-3 testing, please visit <a href=\"http:\/\/www.bg-medicine.com\" rel=\"nofollow\">http:\/\/www.bg-medicine.com<\/a> and <a href=\"http:\/\/www.galectin-3.com\" rel=\"nofollow\">http:\/\/www.galectin-3.com<\/a>.    <\/p>\n<p>      The BG Medicine Inc. logo is available at       <a href=\"http:\/\/www.globenewswire.com\/newsroom\/prs\/?pkgid=10352\" rel=\"nofollow\">http:\/\/www.globenewswire.com\/newsroom\/prs\/?pkgid=10352<\/a>    <\/p>\n<\/p>\n<p><!-- Auto Generated --><\/p>\n<p>View original post here:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/bg-medicine-announce-first-quarter-123000512.html;_ylt=A2KJ2Ug0wYNR.hAAIp3_wgt.\" title=\"BG Medicine to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 9, 2013\">BG Medicine to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 9, 2013<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> WALTHAM, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) today announced that the company will host a conference call and webcast on Thursday, May 9 at 8:30 a.m.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/bg-medicine-to-announce-first-quarter-2013-financial-results-and-host-conference-call-on-thursday-may-9-2013.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-77735","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/77735"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=77735"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/77735\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=77735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=77735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=77735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}